Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

The use of proteasome inhibitors in anti-cancer therapy
  • Home
  • /
  • The use of proteasome inhibitors in anti-cancer therapy
  1. Home /
  2. Archives /
  3. Vol. 10 No. 7 (2020) /
  4. Review Articles

The use of proteasome inhibitors in anti-cancer therapy

Authors

  • Marzena Teresa Baran Chair and Department of Biochemistry and Molecular Biology, Medical University of Lublin https://orcid.org/0000-0002-6985-435X
  • Paulina Miziak Chair and Department of Biochemistry and Molecular Biology, Medical University of Lublin
  • Katarzyna Bonio Department of Cell Biology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Lublin

DOI:

https://doi.org/10.12775/JEHS.2020.10.07.026

Keywords

Ubiquitin, proteasome, proteasome inhibitors, anti-cancer therapy

Abstract

Proteins are the basic building blocks of the human body. Most proteins, after fulfilling their function, are degraded with the help of a multi-catalytic proteolytic complex - the 26S proteasome, thanks to its prior labeling with a poly-ubiquitin chain. The ubiquitin-proteasome complex is involved in the control of many important cellular processes. It is involved in the cell cycle, cell proliferation and growth, apoptosis, control of receptor function, quality of proteins in the endoplasmic reticulum, immune response, stress response and other extracellular factors. The dysfunction of the ubiquitin-proteasome pathway plays an important role in the development of many neurodegenerative and neoplastic diseases, as well as diseases with an immune and infectious origin. Accordingly, research is being conducted where the UPS complex is the target of therapeutic activities. Specific proteasome inhibitors are used in cancer therapy. The first to be approved by the FDA was bortezomib, which is a peptide derivative of boric acid. It has the ability to initiate the process of apoptosis by inhibiting the activity of the NF-κB protein, which is a transcription factor. This compound is used in the treatment of multiple myeloma and malignant lung and breast cancers. There are also studies on the combination of proteasome inhibitors with other chemotherapeuticam. There is still growing interest in research aimed at obtaining substances that allowed to control the mechanisms of proteolytic degradation.

References

Podgórska J., Komórkowy system sprzątający – degradacja proteasomalna i jej rola w terapii onkologicznej, Biotechnologia.pl, 2017

M. Staszczak (2017), Szalak ubikwityna- proteasom, jako cel strategii terapeutycznych, Postępy Biochemii 53 (4), 289-291

Bubko I. i inni, Rola proteasomu w terapii chorób nieuleczalnych, Postepy Hig Med Dosw., 2010; 64: 314-325

Maliński M., Cichocki M., Inhibicja aktywności proteasomu, jako nowa strategia w terapii i chemioprewencji nowotworów, Postepy Hig Med Dosw 2013; 67 : 90-106

N. M. Weathington, R. K. Mallampalli (2014), Emerging therapies targeting the ubiquitin

proteasome system in cancer, The Journal of Clinical Investigation, 124,1

Dees E.C, Orlowski R.Z., 2006, Targeting the ubiquitin–proteasome pathway in breast cancer therapy, Future Oncol. (2006) 2(1), 122

Kazula A., Kazula E., Proteasomy a nowe kierunki terapii, Terapia i Leki., (2009)., tom 65, nr.7

Henshall F.N., Kumar S. T, Ubiquitination and the regulation of membrane proteins. Physiol. Rev. (2017). 97: 253-281

Stój J., Karpowicz P., Proteolityczny kombinat i jego regulatory, Wiadomości chemiczne, (2012), 66

Romaniuk R. i inni, Inhibitory proteasomów w terapii onkologicznej, Postepy Hig Med Dosw., (2015) 69: 1443-1450

Downloads

  • PDF

Published

2020-07-27

How to Cite

1.
BARAN, Marzena Teresa, MIZIAK, Paulina and BONIO, Katarzyna. The use of proteasome inhibitors in anti-cancer therapy. Journal of Education, Health and Sport. Online. 27 July 2020. Vol. 10, no. 7, pp. 231-235. [Accessed 30 September 2023]. DOI 10.12775/JEHS.2020.10.07.026.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 10 No. 7 (2020)

Section

Review Articles

License

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 232
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

Ubiquitin, proteasome, proteasome inhibitors, anti-cancer therapy
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Karmelitański Instytut Duchowości w Krakowie
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop